Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.

L'Oreal and other investors invested ₹65 crore in Deconstruct, a skin care brand. The investment involved L'Oreal's VC fund BOLD and existing investors Kalaari Capital and Beenext. Deconstruct aims to ...